Glenmark Pharma Share Price in Focus on Launching Generic Adderall Tablets in US

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of its generic version of the widely prescribed medication Adderall. 

This development is seen as a timely response to the prevailing shortage of the drug in the United States. With distribution scheduled to commence in May 2025, the launch demonstrates Glenmark’s commitment to enhancing access to essential medicines.

Product Launch to Address Critical Demand in the US

Glenmark’s new offering includes Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulphate and Amphetamine Sulphate Tablets—known collectively as Mixed Salts of a Single Entity Amphetamine Product—available in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths.

The formulation is bioequivalent and therapeutically equivalent to the reference listed drug Adderall®, manufactured by Teva Women’s Health, Inc. According to IQVIA™ sales data, the US market for these tablets reached approximately $421.7 million in sales in the twelve months ending February 2025. The launch is poised to support patients by enhancing the availability of a critical treatment option.

Glenmark’s Global Reach and Sustainable Vision

Commenting on the launch, Marc Kikuchi, President and Business Head, North America, highlighted “Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is a highly prescribed medication in the United States.

Glenmark is very pleased to be able to help alleviate the shortage this country has been facing with this upcoming launch.” 

Glenmark Pharmaceuticals Ltd., the parent company, operates across branded, generic, and OTC product segments, focusing on key therapeutic areas such as cardiometabolic, respiratory, dermatology, and oncology. With 11 manufacturing facilities across four continents and a presence in over 80 countries, Glenmark ranks among the top 100 global biopharmaceutical firms. 

The company’s environmental initiatives, including greenhouse gas emission reduction targets validated by the Science Based Target initiative, further illustrate its holistic approach to healthcare and sustainability.

Glenmark Pharmaceuticals Share Performance 

As of April 17, 2025, at 10:30 AM Glenmark Pharmaceuticals Share Price is trading at ₹1,351.50, reflecting a 0.39% down from the previous close.

Conclusion

The anticipated launch of Glenmark’s generic version of Adderall® marks a significant advancement in the company’s North American strategy. By addressing a pressing market need and showcasing its robust manufacturing and distribution capabilities, Glenmark continues to assert its position as a key global player in the pharmaceutical industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.